IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 17,526 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 17,526 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was purchased at an average price of $1.33 per share, for a total transaction of $23,309.58. Following the purchase, the insider owned 1,174,889 shares in the company, valued at $1,562,602.37. This represents a 1.51% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Performance

Shares of IRIX stock opened at $0.88 on Thursday. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65. The company’s 50-day moving average is $0.73 and its 200 day moving average is $0.95. The company has a market capitalization of $15.46 million, a price-to-earnings ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. As a group, research analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IRIDEX

Several institutional investors have recently modified their holdings of IRIX. Bank of New York Mellon Corp bought a new stake in IRIDEX in the 2nd quarter worth about $29,000. Diversify Advisory Services LLC bought a new position in IRIDEX during the 2nd quarter valued at about $30,000. Diversify Wealth Management LLC bought a new position in IRIDEX during the 1st quarter valued at about $35,000. United Capital Financial Advisors LLC purchased a new stake in shares of IRIDEX during the 2nd quarter valued at about $41,000. Finally, Thompson Davis & CO. Inc. boosted its holdings in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the last quarter. 20.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.00.

IRIDEX News Summary

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.